MannKind | MNKD - Assets


MannKind reported $494.64M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Adma Biologics USD 568.69M 10.31M Sep/2025
Dynavax Technologies USD 946.51M 28.06M Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Insmed USD 2.36B 119.12M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
MannKind USD 494.64M 82.94M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Novo Nordisk DKK 76.18B 412.98B Jun/2025
Pfizer USD 208.73B 2.64B Sep/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Xencor USD 868.81M 10.61M Sep/2025